PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era

Current Opinion in Lipidology
M John ChapmanPCSK9 Forum

Abstract

The first monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) have been approved for clinical use. This timely review highlights recent developments. Low-density lipoprotein cholesterol (LDL-C) is the primary driver of atherosclerosis and the key target for intervention. Yet despite best treatment including statins, attaining sufficient LDL-C lowering can be problematic for high cardiovascular risk patients. The development of PCSK9 inhibitors, driven by novel genetic and mechanistic insights, offers an answer. Removal of circulating PCSK9 increases LDL receptor availability, and thus markedly decreases plasma LDL-C levels (by ∼50-60%), and is additive to the lipid lowering effects of statins and ezetimibe. PCSK9 inhibition also reduces (by 25-30%) plasma levels of lipoprotein(a), a causal factor in atherosclerotic vascular disease, suggestive of partial catabolism of lipoprotein(a) by LDL receptors. The ODYSSEY and PROFICIO (Programme to Reduce LDL-C and Cardiovascular Outcomes Following Inhibition of PCSK9 In Different Populations) clinical trial programmes involving a wide range of high-risk patients, including statin intolerant patients, have confirmed the consistency of the LDL response, e...Continue Reading

References

Jun 13, 2008·Lipids in Health and Disease·Janice MayneMichel Chrétien
Jun 30, 2011·European Heart Journal·UNKNOWN European Association for Cardiovascular Prevention & RehabilitationUNKNOWN ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees
Sep 25, 2012·Journal of Internal Medicine·F Kronenberg, G Utermann
Oct 29, 2013·Journal of the American College of Cardiology·Pia R KamstrupBørge G Nordestgaard
Mar 15, 2014·Circulation Research·Nabil G SeidahMajambu Mbikay
Apr 1, 2014·The New England Journal of Medicine·Dirk J BlomUNKNOWN DESCARTES Investigators
Oct 4, 2014·Arteriosclerosis, Thrombosis, and Vascular Biology·Yascara Grisel Luna SaavedraAlexis Baass
Oct 6, 2014·Lancet·Raul D Santos, Gerald F Watts
Oct 17, 2014·Science Translational Medicine·Keith R WalleyJohn H Boyd
Dec 4, 2014·Journal of the American Heart Association·Liv MundalKjetil Retterstøl
Jan 13, 2015·Journal of General Internal Medicine·Brian R OttThomas A Trikalinos
Feb 20, 2015·European Heart Journal·Erik S StroesUNKNOWN European Atherosclerosis Society Consensus Panel
Mar 17, 2015·The New England Journal of Medicine·Jennifer G RobinsonUNKNOWN ODYSSEY LONG TERM Investigators
Mar 17, 2015·The New England Journal of Medicine·Marc S SabatineUNKNOWN Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators
Mar 31, 2015·Cell·Joseph L Goldstein, Michael S Brown
Apr 26, 2015·Journal of Clinical Lipidology·James M McKenney
May 21, 2015·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Kristopher J Swiger, Seth S Martin
May 27, 2015·European Heart Journal·Albert WiegmanUNKNOWN European Atherosclerosis Society Consensus Panel
Jun 2, 2015·The Journal of Clinical Endocrinology and Metabolism·Harold BaysStephen Donahue
Jun 8, 2015·Diabetologia·Amélie BonnefondUNKNOWN DESIR study group
Aug 20, 2015·The New England Journal of Medicine·Jennifer G Robinson, John J P Kastelein
Aug 22, 2015·The New England Journal of Medicine·Marc S SabatineEvan A Stein

❮ Previous
Next ❯

Citations

Jan 5, 2016·European Heart Journal·M John ChapmanUlf Landmesser
Dec 15, 2016·Paediatrics and International Child Health·Michael France
Apr 2, 2017·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Amir Abbas MomtaziAmirhossein Sahebkar
Feb 24, 2017·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·A E LevensonS D de Ferranti
Aug 22, 2017·Nature Structural & Molecular Biology·Yingnan ZhangDaniel Kirchhofer
Oct 19, 2017·Current Atherosclerosis Reports·Petra El KhouryMarianne Abifadel
Aug 24, 2017·Praxis·Walter F Riesen
Jun 18, 2017·Circulation·Frank M SacksUNKNOWN American Heart Association
Dec 26, 2018·Circulation Research·Stefano SpolituLale Ozcan
Jan 8, 2019·The Nurse Practitioner·J Casey Elkins, Sharon Fruh
Aug 11, 2019·Current Topics in Medicinal Chemistry·Bo ChenPengjun Zhao
May 6, 2016·Current Opinion in Lipidology·Alexander J Blood, Richard A Krasuski
May 24, 2016·Current Opinion in Lipidology·Sergei N PokrovskyMarat V Ezhov
Jan 29, 2017·Current Atherosclerosis Reports·Jaana HartialaHooman Allayee
Feb 9, 2017·Clinical Research in Cardiology Supplements·Rainer Schulz, Klaus-Dieter Schlüter
Jun 24, 2017·Current Treatment Options in Cardiovascular Medicine·Ashwin DurairajSeth Baum
Aug 10, 2018·Hormones : International Journal of Endocrinology and Metabolism·Christos V RizosEvangelos N Liberopoulos
Jan 13, 2019·International Journal of Molecular Sciences·Marica BordicchiaRiccardo Sarzani
Apr 26, 2017·Basic Research in Cardiology·Simon GlerupKlaus-Dieter Schlüter
Nov 7, 2019·The American Journal of Cardiology·Daniel GaudetEvan Stein
May 11, 2021·Clínica e investigación en arteriosclerosis : publicación oficial de la Sociedad Española de Arteriosclerosis·José López-Miranda, Juan Pedro-Botet

❮ Previous
Next ❯

Software Mentioned

ODYSSEY

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Related Papers

Türk Kardiyoloji Derneği arşivi : Türk Kardiyoloji Derneğinin yayın organıdır
Ahmet AvciBülent Behlül Altunkeser
Current Atherosclerosis Reports
Fatima Rodriguez, Joshua W Knowles
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
Michel Farnier
© 2022 Meta ULC. All rights reserved